[1] |
Niebel D, Vos LD, Fetter T, et al. Cutaneous lupus erythematosus:An update on pathogenesis and future therapeutic directions[J].Am J Clin Dermatol,2023,24(4):521-540.DOI:10.1007/s40257-023-00774-8.
|
[2] |
Ranginwala AM,Chalishazar MM,Panja P,et al. Oral discoid lupus erythematosus:A study of twenty-one cases[J]. J Oral Maxillofac Pathol,2012,16(3):368-373. DOI:10.4103/0973-029X.102487.
|
[3] |
Schiødt M,Andersen L. Ultrastructural features of oral discoid lupus erythematosus[J].Acta Derm Venereol,1980,60(2):99-107.DOI:10.2340/000155556099107.
|
[4] |
Warnakulasuriya S,Kujan O,Aguirre-Urizar JM,et al. Oral potentially malignant disorders:A consensus report from an international seminar on nomenclature and classification,convened by the WHO Collaborating Centre for Oral Cancer[J].Oral Dis,2021,27(8):1862-1880.DOI:10.1111/odi.13704.
|
[5] |
Kim DY,Rha EY,Yoo G,et al. Squamous cell carcinoma on the upper lip of a patient with discoid lupus erythematosus[J].Arch Plast Surg,2013,40(2):155-157.DOI:10.5999/aps.2013.40.2.155.
|
[6] |
Fernandes MS,Girisha BS,Viswanathan N,et al. Discoid lupus erythematosus with squamous cell carcinoma:A case report and review of the literature in Indian patients[J]. Lupus,2015,24(14):1562-1566.DOI:10.1177/0961203315599245.
|
[7] |
Liu W,Shen ZY,Wang LJ,et al.Malignant potential of oral and labial chronic discoid lupus erythematosus:A clinicopathological study of 87 cases[J]. Histopathology,2011,59(2):292-298.DOI:10.1111/j.1365-2559.2011.03934.x.
|
[8] |
Yang J,Antin P,Berx G,et al. Guidelines and definitions for research on epithelial-mesenchymal transition[J]. Nat Rev Mol Cell Biol,2020,21(6):341-352. DOI:10.1038/s41580-020-0237-9.
|
[9] |
Meng Z,Yang T,Liu D.Type-2 epithelial-mesenchymal transition in oral mucosal nonneoplastic diseases[J]. Front Immunol,2022,13:1020768.DOI:10.3389/fimmu.2022.1020768.
|
[10] |
Greenburg G,Hay ED. Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells[J]. J Cell Biol,1982,95(1):333-339. DOI:10.1083/jcb.95.1.333.
|
[11] |
Xu Y,Kovacic JC. Endothelial to mesenchymal transition in health and disease[J]. Annu Rev Physiol,2023,85:245-267.DOI:10.1146/annurev-physiol-032222-080806.
|
[12] |
Liao TT,Yang MH.Hybrid epithelial/mesenchymal state in cancer metastasis:Clinical significance and regulatory mechanisms[J].Cells,2020,9(3):623.DOI:10.3390/cells9030623.
|
[13] |
Marconi GD,Fonticoli L,Rajan TS,et al. Epithelial -mesenchymal transition(EMT):The type-2 EMT in wound healing,tissue regeneration and organ fibrosis[J]. Cells,2021,10(7):1587.DOI:10.3390/cells10071587.
|
[14] |
Liu Y,Liu G,Liu Q,et al.The cellular character of liquefaction degeneration in oral lichen planus and the role of interferon gamma[J].J Oral Pathol Med,2017,46(10):1015-1022.DOI:10.1111/jop.12595.
|
[15] |
Liu W,Yao Y,Shi L,et al. A novel lncRNA LOLA1 may predict malignant progression and promote migration,invasion,and EMT of oral leukoplakia via the AKT/GSK-3β pathway[J].J Cell Biochem,2021,122(10):1302-1312. DOI:10.1002/jcb.29951.
|
[16] |
Coopman P,Djiane A. Adherens junction and E - cadherin complex regulation by epithelial polarity[J]. Cell Mol Life Sci,2016,73(18):3535-3553.DOI:10.1007/s00018-016-2260-8.
|
[17] |
Sleeman JP,Thiery JP. SnapShot:The epithelial-mesenchymal transition[J]. Cell,2011,145(1):162.e1. DOI:10.1016/j.cell.2011.03.029.
|
[18] |
Haque M,Shyanti RK,Mishra MK.Targeted therapy approaches for epithelial-mesenchymal transition in triple negative breast cancer[J]. Front Oncol,2024,14:1431418. DOI:10.3389/fonc.2024.1431418.
|
[19] |
Erazo-Martínez V,Tobón GJ,Cañas CA. Circulating and skin biopsy-present cytokines related to the pathogenesis of cutaneous lupus erythematosus[J].Autoimmun Rev,2023,22(2):103262.DOI:10.1016/j.autrev.2022.103262.
|
[20] |
Toro JR,Finlay D,Dou X,et al.Detection of type 1 cytokines in discoid lupus erythematosus[J].Arch Dermatol,2000,136(12):1497-1501.DOI:10.1001/archderm.136.12.1497.
|
[21] |
Malara G,Verduci C,Altomonte M,et al. Thalidomide and discoid lupus erythematosus:Case series and review of literature[J].Drugs Context,2022,11:2021-9-8.DOI:10.7573/dic.2021-9-8.
|
[22] |
Verdelli A,Corrà A,Mariotti EB,et al. An update on the management of refractory cutaneous lupus erythematosus[J].Front Med(Lausanne),2022,9:941003. DOI:10.3389/fmed.2022.941003.
|